Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bionano Genomics, Inc. filings document the formal disclosures of a genome-analysis company commercializing optical genome mapping solutions, diagnostic testing services, genome-analysis software and nucleic acid extraction and purification technologies. Form 8-K reports record financial results, preliminary results, material agreements, securities offerings and executive leadership changes, while registration statements describe offered common stock, pre-funded warrants and warrant securities.
Proxy materials cover board elections, executive compensation, equity-award matters, shareholder voting and governance practices. The filing record also documents capital-structure changes, Nasdaq-listed common stock disclosures, risk factors and exhibits tied to Bionano’s OGM, VIA software, Ionic system and Bionano Laboratories operations.
Bionano Genomics, Inc. (BNGO) reported that Interim Chief Executive and director Albert Luderer purchased 4,000 shares of common stock on September 4, 2026 in an open market or private transaction. The shares are held indirectly through a Traditional IRA, bringing his indirect holdings in that account to 8,000 shares.
Bionano Genomics, Inc. (BNGO) reported that interim Chief Executive and director Albert Luderer indirectly purchased 4,000 shares of Common Stock on 2026-08-21 in an open-market or private transaction at $1.215 per share. The shares are held indirectly through a Traditional IRA, and this filing does not indicate use of a Rule 10b5-1 trading plan.
CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 1,307,135 shares of Bionano Genomics, Inc. common stock, representing 9.9% of the class. The position consists entirely of shares issuable upon exercise of warrants.
The warrants are subject to ownership caps: a portion cannot be exercised if it would cause aggregated beneficial ownership to exceed 4.99%, and the remainder cannot be exercised above 9.99%. Bionano Genomics reported 11,777,300 shares outstanding as of June 30, 2026, which is used to calculate the ownership percentage. Heights Capital Management acts as investment manager to CVI and may be deemed to share voting and dispositive power, while each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Bionano Genomics, Inc. reported higher revenue but continuing losses for the quarter and six months ended June 30, 2026. Total revenue grew to $8.2M for the quarter (up from $6.7M) and $14.9M for the six months (up from $13.2M), driven mainly by instruments and consumables. Quarterly instrument revenue rose 46% to $2.0M and consumables 31% to $4.3M, supported by an installed base of 397 OGM systems and 9,219 flowcells sold in the quarter.
Gross margin was 53% for the quarter, similar to the prior year period. Operating expenses were essentially flat year over year for the six months, but the company remains unprofitable, with a net loss of $7.4M in the quarter and $15.7M year-to-date, widening versus 2025. Accumulated deficit reached $735.3M.
Liquidity is constrained: as of June 30, 2026, Bionano had $3.7M in cash and cash equivalents, $6.2M in short-term investments and $14.8M of working capital. Management used $10.4M of cash in operating activities in the first half and states there is substantial doubt about the company’s ability to continue as a going concern without additional capital. The company fully redeemed its $10.3M JGB convertible debentures at maturity and raised about $1.3M of equity under a $75M at-the-market program.
Bionano Genomics, Inc. reported second quarter 2026 results with continued growth in its optical genome mapping business. For the three months ended June 30, 2026, total revenue was $8.2 million, up 21% from $6.7 million a year earlier, driven largely by consumables and clinical adoption. Consumables revenue reached $4.3 million, up 31%, and 9,219 nanochannel array flow cells were sold, a 27% increase over 7,233 in 2025. GAAP gross margin was 53% versus 52% a year ago, while operating expenses rose 2% to $11.5 million; total adjusted operating expense declined 2% to $8.7 million. The company recorded a GAAP net loss of $7.4 million for the quarter and $15.7 million for the first half of 2026. Management highlighted the completed full retirement of all outstanding Senior Secured Convertible Debentures, eliminating secured debt and related liens, and cited strong growth in OGM-related publications and conference activity. Guidance calls for Q3 2026 revenue of $8.2–$8.6 million and full-year 2026 revenue of $31–$33 million.
Bionano Genomics, Inc. reported that Principal Accounting Officer Mark Adamchak received a grant of 5,000 stock options to buy common stock at an exercise price of $1.12 per share, vesting 50% on each of the first and second anniversaries of the vesting commencement date and expiring on August 2, 2036. This Form 4 replaces an erroneously filed initial Form 3.
Bionano Genomics, Inc. reported that its General Counsel, Jonathan V. Dixon, received a grant of stock options for 15,000 shares of common stock on 2026-08-03. The options have an exercise price of $1.12 per share and expire on 2036-08-02. The award vests 50% on each of the first and second anniversaries of the vesting commencement date, subject to Continuous Service under the company’s 2018 Plan. Following this grant, Dixon holds options covering 15,000 shares. The company also states that this filing replaces an erroneously filed initial Form 3 dated August 5, 2026.
OLDAKOWSKI MARK reported acquisition or exercise transactions in this Form 4 filing.
Bionano Genomics reported a Form 4 for Chief Operating Officer Mark Oldakowski showing a grant of 15,000 stock options to buy common stock at $1.12 per share, expiring in 2036. The options vest 50% on each of the first two anniversaries of the vesting commencement date, subject to continuous service.
Bionano Genomics, Inc. reported an equity award to Chief Scientific Officer Alex Reid Hastie of a stock option covering 54,000 shares of common stock at an exercise price of $1.12 per share, expiring August 2, 2036. Twenty-five percent vests August 2, 2027, with the balance vesting in 36 monthly installments, and the report replaces an earlier erroneous initial ownership statement filed August 5, 2026.
Bionano Genomics, Inc. reports that Chief Operating Officer Mark Oldakowski beneficially owns a stock option giving the right to buy 15,000 shares of Common Stock at an exercise price of $1.12 per share. The option expires on August 2, 2036. According to the equity plan footnote, the shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case conditioned on the executive’s Continuous Service, as defined in the company’s 2018 plan. The position is reported as direct ownership.